Scott B. Sellinger, MD, FACS, presented “How to Best Select Doublet vs. Triplet Therapy in MCSPC” during the 24th Future Directions in Urology Symposium in August 2024 in Colorado Springs, Colorado.
How to cite: Sellinger, Scott B. “How to Best Select Doublet vs. Triplet Therapy in MCSPC.” August 2024. Accessed Dec 2024. https://grandroundsinurology.com/how-to-best-select-doublet-vs-triplet-therapy-in-mcspc/
How to Best Select Doublet vs. Triplet Therapy in MCSPC – Summary
Scott B. Sellinger, MD, FACS, addresses key considerations in deciding between doublet and triplet therapies for metastatic castration-sensitive prostate cancer.
In this 12-minute presentation, Dr. Sellinger highlights the superiority of androgen deprivation therapy (ADT) combined with androgen pathway inhibitors. He discusses evidence from pivotal trials, including TITAN, ARCHES, PEACE-1, and ARASENS, demonstrating that doublet and triplet therapies offer superior survival benefits compared to ADT alone.
Sellinger emphasizes that selecting between doublet and triplet therapy is both an art and a science, balancing clinical guidelines with patient-specific factors such as age, comorbidities, and access to treatment. While higher volume and symptomatic patients might benefit from more intensive triplet therapy, the importance of patient preference, PSA response, and cost considerations is underscored. He suggests that establishing clearer guidelines on doublet versus triplet therapy could help practitioners make more confident decisions for their patients in this nuanced field.
The Future Directions in Urology Symposium (FDUS) is an annual urology think tank and non-CME educational summit that brings together industry figures and experts to discuss the current state of genitourinary care and define future directions in treatment. Dr. Dreicer delivered this educational activity during the 24th iteration of the meeting in August 2024 in Colorado Springs, Colorado.
ABOUT THE AUTHOR
Scott B. Sellinger, MD, FACS, is president of Advanced Urology Institute in Tallahassee, Florida. He has been a partner at Southeastern Urological Center, now a division of Advanced Urology Institute, since 1991. Dr. Sellinger earned his medical degree from the University of Florida in Gainesville, prior to which he received his BS degree in chemistry from Syracuse University in New York. He completed his urology residency at the University of Florida and has lived in Tallahassee for over 32 years.
Dr. Sellinger was president of the Capital Medical Society in 2003 and served as president of the Florida Urological Society in 2005. In 2018, Dr. Sellinger served as president of the Southeastern Section of the American Urological Association (SESAUA). In 2019, he served as president of the American Association of Clinical Urologists (AACU). In addition to his urology specific work, Dr. Sellinger has developed a special interest in risk management and prevention of medical errors and has lectured extensively on this subject. He is also interested in large group practice development and management. For several years, Dr. Sellinger has served on the board of Advanced Urology Institute (AUI) representing his care center in Tallahassee. In January 2021, he became the second president of AUI, now one of the largest independent urology practices in the United States. Dr. Sellinger currently chairs the Advanced Prostate Cancer (APC) committee and oversees seven APC clinics within AUI. Since 2015, he has also served on the Large Urology Group Practice Association (LUGPA) Board of Directors, where he currently serves as President-Elect. At LUGPA, he is proud to represent over 2300 urologists by working to preserve and advance the independent practice of urology.
